On September 8, 2026, Pharvaris N.V. announced positive topline data from the CHAPTER-3 pivotal study of deucrictibant XR for the prophylaxis of hereditary angioedema (HAE) attacks. This clinical milestone provides critical evidence supporting the regulatory approval pathway for its lead asset in preventing HAE episodes. The company operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for rare diseases.

Pharvaris N.V. reported second quarter 2026 financial results and provided business updates for the period ended June 30, 2026. The company held €318 million in cash and cash equivalents as of June 30, 2026. R&D expenses were €35.0 million and G&A expenses were €15.8 million, resulting in a net loss of €47.8 million or €0.70 per share. The company announced the promotion of Peng Lu to President effective June 2026. Pharvaris closed a $132.3 million underwritten offering in May 2026, extending its cash runway into 2028. Topline data from the pivotal Phase 3 CHAPTER-3 study of deucrictibant XR is expected in Q3 2026. The FDA accepted the NDA for deucrictibant IR with a PDUFA date of April 23, 2027, and the EMA validated the MAA in July 2026. Enrollment continues in the CREAATE Phase 3 study for AAE-C1INH. Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for hereditary and acquired angioedema.